Ubs Asset Management Americas Inc Janux Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 165,737 shares of JANX stock, worth $5.31 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
165,737
Previous 26,194
532.73%
Holding current value
$5.31 Million
Previous $1.19 Million
646.26%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding JANX
# of Institutions
228Shares Held
55.1MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$332 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$114 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$113 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$98 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$75 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.33B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...